Opendata, web and dolomites

ART-AI SIGNED

AI-powered Adaptive radiation dosimetry: An innovative solution for safer and precise MRI guided RadioTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ART-AI" data sheet

The following table provides information about the project.

Coordinator
THERAPANACEA 

Organization address
address: 24 RUE DU FAUBOURG SAINT-JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙539˙583 €
 EC max contribution 2˙477˙708 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THERAPANACEA FR (PARIS) coordinator 2˙477˙708.00

Map

 Project objective

Current radiotherapy is fully reliant on semi-automatic treatment planning systems (TPS) that depend on highly toxic CT scans and human clinical expertise for creating a treatment plan. As a result, the procedure is inefficient and inefficacious resulting in poor treatment outcome and severe side effects. In recent years, there has been an emergence of the concept of MRI-guided radiotherapy, wherein non-toxic and high resolution MRI images are used to guide treatment planning. As a result, several key players in the radiotherapy market such as Elekta and ViewRay have introduced MRI embedded linear acclerators to perform MRI imaging during radiotherapy administration. However, as of yet no TPS exists on the market that enables fully automated MRI-guided radiotherapy, in order to provide real-time dose adjustment.

To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.

In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ART-AI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ART-AI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More  

BEMYEYES (2019)

Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More